As of September 1st, the Special Authority criteria for empagliflozin (Jardiance), dulaglutide (Trulicity) and liraglutide (Victoza) has been refined to open access to these medications previously unavailable to all people living with type 2 diabetes who have an HbA1c > 53 mmol/mol despite regular use of other glucose-lowering medications. This is in line with the evidence-based therapies recommended in the National Diabetes Roadmap and removes the need for additional clinic visits and testing. People with type 2 diabetes and cardiovascular and/or renal disease will benefit from SGLT2i and/or GLP1Ra use irrespective of their HbA1c and it is important to continue to focus on our high-risk populations, particularly Māori and Pacific peoples. As is current practice, where appropriate, clinicians should consider the heart failure Special Authority for empagliflozin or discuss self-funding, including using the Disability Allowance. Click HERE for the Pharmac announcement